Breast Cancer Trial, Not Yet Recruiting NCT07484763 Sponsor: Shengjing Hospital Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Not Yet Recruiting

NCT07484763
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been diagnosed with invasive breast cancer (specifically ductal or lobular type), confirmed through laboratory testing of tissue samples.
  • People whose cancer is hormone receptor-positive and HER2-negative, meaning the cancer cells respond to hormones (at a level of 10% or more) and do not have high levels of the HER2 protein, as confirmed by specific lab tests.
  • People who have received standard surgery and hormone-blocking therapy either before or after surgery as part of their breast cancer treatment.
  • People for whom complete medical records and follow-up information are available.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whose cancer had already spread to distant parts of the body (Stage IV) at the time of diagnosis.
  • People who are male and have been diagnosed with breast cancer.
  • People for whom important medical or pathology records are missing or who were lost to follow-up during their care.
  • People whose cancer tests show a high level of HER2 protein (a result described as 3+, or 2+ with gene amplification confirmed by a specific test called FISH).
  • People whose cancer is triple-negative breast cancer (a type that does not respond to hormones and also does not have high HER2 levels).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Shengjing Hospital
Registry
ClinicalTrials.gov
Start date
1 April 2026
Est. completion
1 July 2026

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Primary endpoints

Disease-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov